Is afatinib (Gitairin) a first- or second-generation targeted drug and its characteristics?

Afatinib is a second-generation EGFR-targeted drug. It is a new generation of irreversible inhibitors developed after the first-generation EGFR-TKIs such as gefitinib and erlotinib. It was developed by the German company Boehringer Ingelheim and is mainly used to treat patients with non-small cell lung cancer (NSCLC) with EGFR gene-sensitive mutations. Compared with the first-generation drugs, afatinib has stronger binding capacity and a broader inhibitory spectrum. It can act on receptor family members such as EGFR, HER2 and HER4 at the same time, so it can maintain a certain efficacy in certain drug-resistant conditions.

The main feature of afatinib is its irreversible binding mechanism. It causes long-term inhibition of receptor activity by forming covalent bonds with key cysteine u200bu200bresidues of receptor tyrosine kinases. This combination makes the inhibition of tumor cells by afatinib more durable and difficult to be reversed by transient high-concentration EGF signals. In addition, it is not only effective against common EGFR mutations (such as Del19, L858R), but also against a few rare mutation subtypes ( For example, G719X, S768I, L861Q) have shown better activity, which makes their clinical application scope wider than that of the first-generation drugs.

Compared with first-generation EGFR-TKI (such as gefitinib, erlotinib), afatinib performs better in terms of duration of efficacy, progression-free survival (PFS), and ability to control patients with brain metastases. Multiple clinical trials (such as the LUX-Lung series of studies) have shown that afatinib can significantly prolong the median PFS in EGFR mutation-positive patients, and the response time of some patients can exceed 12 months. At the same time, its irreversible mechanism of action helps delay the emergence of drug-resistant mutations. However, afatinib has a slightly higher incidence of adverse reactions such as rash and diarrhea, so it is necessary to balance efficacy and tolerability during use.

At present, afatinib has been included in multinational lung cancer treatment guidelines forEGFRSensitive mutation-positive First-line treatment of NSCLC. Since its metabolic pathway is mainly liver metabolism, patients with abnormal liver function or elderly patients should use the drug with caution. Clinically, it is usually recommended to take it once a day on an empty stomach, and adjust the dose according to adverse reactions. Overall, as a second-generation EGFR-targeted drug, afatinib provides a more efficient targeted treatment option for patients with non-small cell lung cancer due to its strong and durable inhibitory characteristics.

Reference materials:https://www.drugs.com/